Pulmonary Arterial Hypertension Clinical Trials in Nashville, Tennessee

8 studies are recruiting for pulmonary arterial hypertension in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

   This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   43 in total

   Run by

   Inhibikase Therapeutics

   See if you can join NCT07365332 on ClinicalTrials.gov

2. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

3. The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

   Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years. Increasing physical activity is highly efficacious in PAH, resulting in six-minute walk di…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT05464095 on ClinicalTrials.gov

4. Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

   Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   3 in total

   Run by

   Gustavo A Heresi, MD, MS

   See if you can join NCT06992440 on ClinicalTrials.gov

5. Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

   The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.

   Stage

   Phase 2

   Ages

   1 to 17

   Site

   Monroe Carell Jr. Children's Hospital ( Site 1601), Nashville, Tennessee

   Locations

   35 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05587712 on ClinicalTrials.gov

6. Mobile Health Intervention to Improve Exercise in Pediatric PH

   Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations. In adults, investigators recently demonstrated that lower baseline daily step counts associated with increased risk of hospitalization and worsening WHO functional cl…

   Stage

   Not phased

   Ages

   10 to 21

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT06549452 on ClinicalTrials.gov

7. Pulmonary Hypertension Association Registry

   The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care C…

   Stage

   Not phased

   Ages

   0 and older

   Site

   Vanderbilt Children's Hospital, Nashville, Tennessee

   Locations

   52 in total

   Run by

   Pulmonary Hypertension Association, Inc.

   See if you can join NCT04071327 on ClinicalTrials.gov

8. Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

   Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe t…

   Stage

   Not phased

   Ages

   0 to 21

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   14 in total

   Run by

   New York Medical College

   See if you can join NCT02249923 on ClinicalTrials.gov